Centre for Integrative Physiology, School of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, United Kingdom.
Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7172-6. doi: 10.1073/pnas.1015723108. Epub 2011 Apr 11.
Naturally occurring mutations of G protein-coupled receptors (GPCRs) causing misfolding and failure to traffic to the cell surface can result in disease states. Some small-molecule orthosteric ligands can rescue such misfolded receptors, presumably by facilitating their correct folding and shuttling to the plasma membrane. Here we show that a cell-permeant, allosterically binding small-molecule agonist (Org 42599) rescues the folding and cell surface expression, and therefore target cell signaling, of mutant human luteinizing hormone (LH) receptors (A593P and S616Y) that cause Leydig cell hypoplasia in man. Both mutant receptors were retained in the cytoplasm whereas WT receptor localized at the cell membrane, and binding of LH to cells expressing the mutant receptors was markedly lower than to those expressing the WT receptor. Incubation with Org 42599 increased mutant receptor expression, cell surface localization, and the proportion of mutant receptor in the mature glycosylated form. Importantly, although LH stimulated little (S616Y) or no (A593P) activation of cells expressing mutant receptors, incubation of cells with Org 42599 facilitated rescue of expression and stimulation by the native ligand, LH. Although Org 42599 could activate these receptors, it could not displace (125)I-labeled human LH binding to the WT receptor, indicating that it acts in an allosteric manner. Here we demonstrate a small-molecule GPCR allosteric agonist that functionally rescues intracellularly retained mutant LH receptors by facilitating their cell surface expression. This approach may have application for treatment of infertile patients bearing such mutations and, more broadly, for other misfolded GPCR mutants resulting in human pathologic processes.
天然存在的 G 蛋白偶联受体 (GPCR) 突变会导致错误折叠和无法运输到细胞表面,从而导致疾病状态。一些小分子正构配体可以挽救这种错误折叠的受体,推测是通过促进其正确折叠和转运到质膜。在这里,我们表明一种细胞渗透性、变构结合的小分子激动剂 (Org 42599) 可以挽救突变型人促黄体生成激素 (LH) 受体 (A593P 和 S616Y) 的折叠和细胞表面表达,从而挽救其靶细胞信号转导,这些受体在人体内导致 Leydig 细胞发育不全。两种突变受体都滞留在细胞质中,而 WT 受体定位于细胞膜,并且与表达突变受体的细胞结合的 LH 明显低于与表达 WT 受体的细胞结合的 LH。用 Org 42599 孵育增加了突变受体的表达、细胞表面定位和成熟糖基化形式的突变受体比例。重要的是,尽管 LH 刺激表达突变受体的细胞很少 (S616Y) 或没有 (A593P) 激活,但 Org 42599 的孵育促进了表达和天然配体 LH 的刺激的挽救。尽管 Org 42599 可以激活这些受体,但它不能置换 (125)I 标记的人 LH 与 WT 受体的结合,表明它以变构方式起作用。在这里,我们证明了一种小分子 GPCR 变构激动剂,它通过促进细胞表面表达来功能性地挽救细胞内滞留的突变型 LH 受体。这种方法可能适用于治疗携带此类突变的不孕患者,并且更广泛地适用于导致人类病理过程的其他错误折叠的 GPCR 突变体。